期刊文献+
共找到8篇文章
< 1 >
每页显示 20 50 100
枢丹 地塞米松 异丙嗪防治化疗胃肠道副反应36例 被引量:1
1
作者 翁春花 《中国疗养医学》 1998年第6期78-79,共2页
关键词 胃肠道副反应 地塞米松 防治化疗 异丙嗪 枢丹 胃肠道反应 化疗药物 化疗方案 5一羟色胺 中枢神经系统
全文增补中
恩丹西酮防治化疗所致恶心呕吐的疗效分析
2
作者 曲惠敬 苏维国 张恩宁 《中国药业》 CAS 1997年第10期30-30,共1页
关键词 恩丹西酮 恶心呕吐 疗效分析 防治化疗 枢复宁 毒副作用 化疗方案 阿霉素 烟台市 大剂量
下载PDF
耳穴埋籽配合足三里穴位注射防治化疗引起的恶心呕吐的效果分析
3
作者 赵娜 李慧霞 《智慧健康》 2022年第36期124-127,243,共5页
目的观察化疗后恶心呕吐患者应用耳穴埋籽配合足三里穴位注射的临床效果。方法选取本院2018年10月-2021年2月化疗患者为研究样本,使用简单随机抽样法从其中选取90例化疗患者,并以奇偶数法分为研究组和对照组,各45例。对照组患者注射胃... 目的观察化疗后恶心呕吐患者应用耳穴埋籽配合足三里穴位注射的临床效果。方法选取本院2018年10月-2021年2月化疗患者为研究样本,使用简单随机抽样法从其中选取90例化疗患者,并以奇偶数法分为研究组和对照组,各45例。对照组患者注射胃复安以预防恶心呕吐,研究组患者则应用耳穴埋籽配合足三里穴位注射的方法进行预防,比较两组患者恶心程度、呕吐程度、治疗满意度以及理疗总有效率。结果研究组患者恶心程度为0度的比例为60.00%,1度的比例为24.44%,2度的比例为8.89%,3度的比例为6.67%,可知研究组患者恶心程度显著低于对照组(χ^(2)=15.000,P<0.001;χ^(2)=5.414,P=0.020;χ^(2)=11.791,P=0.001;χ^(2)=10.000,P=0.002)。研究组患者呕吐程度为0度的比例为53.33%,1度的比例为35.56%,2度的比例为6.67%,3度的比例为4.44%,可知研究组患者呕吐程度显著低于对照组(χ^(2)=14.221,P<0.001;χ^(2)=6.016,P=0.014;χ^(2)=11.275,P=0.001;χ^(2)=5.466,P=0.019);研究组患者理疗有效率为91.11%,显著高于对照组(P<0.05);研究组总满意率为95.56%,显著高于对照组(χ^(2)=6.154,P=0.013)。结论耳穴埋籽配合足三里穴位注射法能够有效预防因化疗引起的恶心、呕吐情况,提高理疗效果,从而提高患者舒适度,有利于提升患者对化疗不良反应防治的满意度,具有较高临床应用价值。 展开更多
关键词 耳穴埋籽 足三里注射 化疗防治 恶心呕吐
下载PDF
恩丹西酮与胃复安防治化疗引起恶心呕吐的对比观察
4
作者 鲁群 《中国基层医药》 CAS 1997年第3期38-38,共1页
顺铂通常被认为是最强的致吐剂。加用Vp-16、环磷酰胺的联合化疗常引起严重的恶心呕吐,可致代谢紊乱、体力下降、精神不振,使很有效的化疗中途被迫中止,严重影响病人的预后。本文报道我科在肺癌化疗前后应用恩丹西酮和胃复安防治恶心呕... 顺铂通常被认为是最强的致吐剂。加用Vp-16、环磷酰胺的联合化疗常引起严重的恶心呕吐,可致代谢紊乱、体力下降、精神不振,使很有效的化疗中途被迫中止,严重影响病人的预后。本文报道我科在肺癌化疗前后应用恩丹西酮和胃复安防治恶心呕吐的对比观察结果。 展开更多
关键词 恩丹西酮 胃复安 恶心呕吐 对比观察 防治化疗 止吐药物 联合化疗 肺癌化疗 顺铂 代谢紊乱
原文传递
旋复代赭汤加味联合恩丹西酮预防化疗恶心呕吐疗效观察 被引量:3
5
作者 袁通春 江劲波 《中医药临床杂志》 2007年第1期4-5,共2页
目的观察旋复代赭汤加味联合恩丹西酮预防化疗恶心呕吐的临床疗效。方法30例肿瘤患者,每例2个疗程计为2例次(化疗方案不变),随机分治疗组与对照组,治疗组以旋复代赭汤加味联合恩丹西酮治疗,对照组单用恩丹西酮治疗。结果2组预防恶心、... 目的观察旋复代赭汤加味联合恩丹西酮预防化疗恶心呕吐的临床疗效。方法30例肿瘤患者,每例2个疗程计为2例次(化疗方案不变),随机分治疗组与对照组,治疗组以旋复代赭汤加味联合恩丹西酮治疗,对照组单用恩丹西酮治疗。结果2组预防恶心、呕吐有效率比较,均差异显著(P<0.05)。结论旋复代赭汤加味联合恩丹西酮能有效防治化疗恶心呕吐反应。 展开更多
关键词 化疗副反应防治 恩丹西酮 中药
下载PDF
Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease 被引量:2
6
作者 Jean-Claude Trinchet Nathalie Ganne-Carrié +2 位作者 Pierre Nahon Gisèle N’kontchou Michel Beaugrand 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第17期2455-2460,共6页
Hepatitis C virus (HCV) is a major cause of hepatocellular carcinoma (HCC) worldwide due to the high prevalence of HCV infection and the high rate of HCC occurrence in patients with HCV cirrhosis. A striking increase ... Hepatitis C virus (HCV) is a major cause of hepatocellular carcinoma (HCC) worldwide due to the high prevalence of HCV infection and the high rate of HCC occurrence in patients with HCV cirrhosis. A striking increase in HCC incidence has been observed during the past decades in most industrialized countries, partly related to the growing number of patients infected by HCV. HCC is currently the main cause of death in patients with HCV-related cirrhosis, a fact that justifies screening as far as curative treatments apply only in patients with small tumors. As a whole, treatment options are similar in patients with cirrhosis whatever the cause. Chemoprevention could be also helpful in the near future. It is strongly suggested that antiviral treatment of HCV infection could prevent HCC occurrence, even in cirrhotic patients, mainly when a sustained virological response is obtained. 展开更多
关键词 Hepatocellular carcinoma CIRRHOSIS Hepatitis C virus EPIDEMIOLOGY SCREENING Treatment PREVENTION
下载PDF
OPTIMIZATION OF TETRANDRINE TREATMENT IN RAT HEPATIC FIBROSIS MODEL
7
作者 潘勤 李定国 +2 位作者 陆汉明 徐芹芳 陈锡美 《Journal of Shanghai Second Medical University(Foreign Language Edition)》 CAS 2006年第1期26-31,共6页
Objective To optimize the therapeutic dosage of tetrandrine (Tet) in rat hepatic fibrosis roodel. Methods 50 Wistar rats were divided into 5 groups at random including normal control, model control, Tettreated model... Objective To optimize the therapeutic dosage of tetrandrine (Tet) in rat hepatic fibrosis roodel. Methods 50 Wistar rats were divided into 5 groups at random including normal control, model control, Tettreated model groups of 10mg· kg^ - 1· d^ - 1, 5mg· kg^ - 1· d^ - 1 and 2.5mg· kg^ - 1· d^ - 1( n = 10 in each group ). All rats, except for the normal controls, were injected with axenic porcine serum (0. 5ml each time, twice a week) intraperitoneally for 8 weeks to establish hepatic fibrosis. After the 8th week, rats of Tet-treated model groups were given by gavage once a day with different doses of Tet for another 8 weeks. Then the liver function, serum levels of hyaluronic acid ( HA ), laminin ( LM), and procollagen type Ⅲ (PCⅢ) were tested. Collagen type 1 and Ⅲ, pathological changes in liver tissue were also assessed. Results Most indices of liver function including alanine minotransferase (ALT), aspartate aminotransferase (AST), albumin ( ALB), albumin/globulin ratio ( A/G) and alkaline phosphatase (ALP) improved significantly in Tet-treated groups with the exception of γ-glutamyl transpeptidase (γ- GT) and total bilirubin (TBIL). Secondly, markedly lowered levels of HA, LM and collagen type I, III were also detected by radioimmunology and immunohistochemistry in the 5 mg· kg^ - 1· d^ - 1 Tet-treated model group. Moreover, pathologi- cal findings confirmed the statistically significant improvement in hepatofibrotic degree resulted from the treatment of 5mg· kg^ - 1· d^ - 1 rather than other doses of Tet. Conclusion For experimental Wistar rats, Tet exhibited an anti-hepatofibrotic action in doses within the range of 2.5mg· kg^ - 1· d^ - 1 to 10mg· kg^ - 1· d^ - 1 and 5mg· kg^ - 1· d^ - 1 may be the optimum one among all doses. 展开更多
关键词 tetrandrine hepatic fibrosis liver function extraceUular matrix pathology
下载PDF
Biochemical Mechanisms of Therapeutic and Prophylactic Effects of Bioflavonoids
8
作者 Olga Makarenko Anatoly Levitsky 《Journal of Pharmacy and Pharmacology》 2016年第8期451-456,共6页
In the present study to investigate the biochemical mechanisms of therapeutic and prophylactic action of bioflavonoids, carried out a comparative evaluation of antioxidant and antiproteinase properties of certain biof... In the present study to investigate the biochemical mechanisms of therapeutic and prophylactic action of bioflavonoids, carried out a comparative evaluation of antioxidant and antiproteinase properties of certain bioflavonoids standards in vitro. Therapeutic and prophylactic efficacy of individual bioflavonoids as well as herbal medicines with bioflavonoids, was examined at an experimental pathology (toxic hepatitis, dental caries, periodontitis, stomatitis, dysbiosis, diabetes Types 1 and 2, gastric ulcer, osteopenia) in Wistar line rats. Condition of organs and tissues was assessed by biochemical markers of inflammation, antioxidant and antimicrobial defense systems of animals. Research has shown the ability ofbioflavonoids in varying degrees inhibit the formation of superoxide anion radicals and malondialdehyde, recover free radicals, bind ions of Fe2+, inhibiting the activity of proteases, such as leukocyte elastase. Established partially competitive type of trypsin and elastase activity inhibition by bioflavonoids. Was revealed a positive effect of bioflavonoids in experimental pathology on animals. Therapeutic and prophylactic effects of bioflavonoids, in our opinion, are realized through a strong antioxidant and antiprotease properties of these compounds. 展开更多
关键词 BIOFLAVONOIDS antioxidant and antiprotease properties in vitro experimental therapy.
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部